Last $48.55 USD
Change Today +0.43 / 0.89%
Volume 6.2M
As of 8:04 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (ABBV) Snapshot

Open
$47.92
Previous Close
$48.12
Day High
$48.78
Day Low
$47.72
52 Week High
12/16/13 - $54.78
52 Week Low
06/13/13 - $40.10
Market Cap
77.5B
Average Volume 10 Days
8.5M
EPS TTM
$2.87
Shares Outstanding
1.6B
EX-Date
04/11/14
P/E TM
16.9x
Dividend
$1.68
Dividend Yield
3.34%
Current Stock Chart for ABBVIE INC (ABBV)

abbvie inc (ABBV) Related Businessweek News

View More BusinessWeek News

abbvie inc (ABBV) Details

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.

25,000 Employees
Last Reported Date: 02/21/14
Founded in 2012

abbvie inc (ABBV) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $790.0K
Executive Vice President of Commercial Operat...
Total Annual Compensation: $710.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $640.2K
Executive Vice President of Business Developm...
Total Annual Compensation: $900.0K
Compensation as of Fiscal Year 2013.

abbvie inc (ABBV) Key Developments

AbbVie Inc. Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer

AbbVie Inc. announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The trial will compare patients randomized to receive either the standard chemotherapies of carboplatin and paclitaxel with the addition of veliparib, versus patients receiving carboplatin and paclitaxel with the addition of placebo. This randomized, placebo-controlled, double-blind, multicenter, Phase III trial will recruit approximately 900 patients. The primary efficacy outcome of the trial is overall survival (OS). Other pre-specified outcome measures include progression-free survival (PFS), and objective response rate (ORR). The safety of veliparib will also be evaluated in the trial.

AbbVie to Present Late-Breaking Results from Turquoise-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress

AbbVie announced that new, detailed results from its hepatitis C development program will be presented April 12, 2014 at the International Liver Congress(TM) (ILC) 2014. Data from a pivotal phase III study, TURQUOISE-II, will be presented as a late-breaker. Additionally, results from the study have been published online in The New England Journal of Medicine. TURQUOISE-II is a global, multi-center, randomized, open-label study evaluating the efficacy and safety of 12 weeks or 24 weeks of treatment with AbbVie's regimen with ribavirin (RBV) in adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection with compensated liver cirrhosis. Patients achieved sustained virologic response rates 12 weeks post-treatment (SVR(12)) of 91.8% and 95.9% in the 12-week and 24-week treatment arms, respectively. Patients in the study were either new to therapy or treatment-experienced (failed previous treatment with pegylated interferon and RBV). Discontinuation rates due to adverse events were 1.9% (four patients) and 2.3% (four patients) in the 12-week and 24-week arms, respectively. The most commonly reported adverse events (>10% in either arm) in TURQUOISE-II were fatigue, headache, nausea, pruritus, insomnia, diarrhea, asthenia, rash, cough, irritability, anemia and dyspnea. On-treatment virologic failure occurred in one patient (0.5%) in the 12-week arm and three patients (1.7%) in the 24-week arm. In addition, 12 patients (5.9%) in the 12-week arm and one patient (0.6%) in the 24-week arm experienced relapse within 12 weeks post-treatment. The AbbVie investigational regimen consists of the fixed-dose combination of ABT-450/ritonavir (150/100mg) co-formulated with ombitasvir (ABT-267) 25mg, dosed once daily, and dasabuvir (ABT-333) 250mg with or without RBV (weight-based), dosed twice daily. The combination of three different mechanisms of action interrupts the HCV replication process with the goal of optimizing SVR rates across different patient populations. The AbbVie HCV clinical development program is intended to advance scientific knowledge and clinical care by investigating an interferon-free, all-oral regimen with and without RBV with the goal of producing high SVR rates in as many patients as possible, including those that typically do not respond well to treatment, such as previous non-responders to interferon-based therapy or patients with advanced liver fibrosis or cirrhosis. ABT-450 was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals for HCV protease inhibitors and regimens that include protease inhibitors. ABT-450 is being developed by AbbVie for use in combination with AbbVie's other investigational medicines for the treatment of HCV. Ribavirin and ritonavir are not approved for the investigational use discussed above, and no conclusions can or should be drawn regarding the safety or efficacy of these products for this use. There are special safety considerations when prescribing these drugs in approved populations. Ritonavir must not be used with certain medications due to significant drug-drug interactions and in patients with known hypersensitivity to ritonavir or any of its excipients. Ribavirin monotherapy is not effective for the treatment of chronic hepatitis C virus and must not be used alone for this use. Ribavirin causes significant teratogenic effects and must not be used in women who are pregnant or breast-feeding and in men whose female partners are pregnant. Ribavirin must not be used in patients with a history of severe pre-existing cardiac disease, severe hepatic dysfunction or decompensated cirrhosis of the liver, autoimmune hepatitis, hemoglobinopathies, or in combination with peginterferon alfa-2a in HIV/HCV co-infected patients with cirrhosis and Child-Pugh score >=6.

AbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C Development Program

AbbVie will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress in London, April 9-13. Detailed results from the SAPPHIRE-I, SAPPHIRE-II, PEARL-III, and TURQUOISE-II studies will be presented at the ILC on April 10-12. In presentations at the ILC, investigators will share detailed data results of four studies from AbbVie's phase III clinical trial program, the phase III program of an investigational, all-oral, interferon-free regimen for the treatment of chronic hepatitis C virus infection in genotype 1 adult patients. The list of AbbVie's phase III clinical trial program data being presented at the ILC, SAPPHIRE-II: Phase III Placebo-Controlled Study of an Investigational Interferon-Free, 12-Week Regimen in 394 Treatment-Experienced Adults with HCV GT1Oral Presentation: General Session 1 and Opening April 10, 14:00-14:15 BST; ICC Auditorium; SAPPHIRE-I: Phase III Placebo-Controlled Study of an Investigational Interferon-Free, 12-Week Regimen in 631 Treatment-Naive Adults with HCV GT1Oral Presentation: General Session 2 and Awards 1April 11, 10:15-10:30 BST; ICC Auditorium; PEARL-III: Sustained Virologic Response 12 Weeks Post-treatment with an Investigational 12-Week Regimen in 419 Treatment-Naive HCV GT1b-Infected Adults Late Breaker Poster: Poster P1299 April 12, 9:00-18:00 BST; Poster Exhibition; TURQUOISE-II: SVR12 Rates in 380 HCV GT1-Infected Adults with compensated Cirrhosis Treated with an Investigational Regimen Oral Presentation: Late Breakers April 12, 15:30-15:45 BST; ICC Auditorium.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:US $48.55 USD +0.43

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $38.93 USD +0.55
Amgen Inc $115.46 USD -0.08
AstraZeneca PLC 3,782 GBp +23.00
Bristol-Myers Squibb Co $49.46 USD +0.35
Eli Lilly & Co $60.43 USD +0.47
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 19.0x
Price/Sales 4.2x
Price/Book 17.2x
Price/Cash Flow 18.8x
TEV/Sales 2.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.